Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-M
Go back to Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-M| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 240.36 -2.74 (1.13%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $243.10 | 52 Week High | $333.65 | |||
| Open | $242.02 | 52 Week Low | $223.02 | |||
| Day High | $243.32 | P/E | 30.78 | |||
| Day Low | $240.15 | EPS | $7.81 | |||
| Volume | 286,684 | |||||



